Core Viewpoint - Huaren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the listing of the raw material drug Bumetanide, which is indicated for severe heart failure, acute pulmonary edema, and adult hypertension, enhancing the company's product line and market competitiveness [1] Group 1 - The approval of Bumetanide will enrich the company's raw material drug product line [1] - The drug is effective for severe heart failure, acute pulmonary edema, and adult hypertension, showcasing its strong diuretic properties [1] - The approval is expected to boost the company's market sales and enhance its competitive edge [1] Group 2 - The development will support the synergistic growth of the company's raw material drugs, formulations, medical devices, and medical packaging sectors [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-040 华仁药业股份有限公司 关于全资子公司布美他尼原料药获得上市申请批准 1．通用名称：布美他尼 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 二、药品的其他情况 布美他尼适用于成人严重心力衰竭，包括急性肺水肿；成人高血压，在短期 内伴有危及生命的内脏疾病（高血压急症），尤其是在以下情况下：高血压脑病， 左心室失代偿伴肺水肿；成人心脏、肾脏、肝硬化引起的严重钠潴留。布美他尼 通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"布 美他尼"《化学原料药上市申请批准通知书》（通知书编号：2025YS00519）。现 将相关情况公告如下： 一、原料药登记信息 三、对公司的影响 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-039 华仁药业股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）根据《公司法》等相关规定，于 2025 年 6 月 23 日召开职工代表大会，会议选举王梦辰先生（简历详见附件）担任公司 第八届董事会职工代表董事，任期自本次职工代表大会审议通过之日起至公司第八 届董事会任期届满之日止。 王梦辰先生符合《公司法》等规定的职工代表董事任职资格和条件。王梦辰先 生担任职工代表董事后，公司董事会中兼任公司高级管理人员以及由职工代表担任 的董事人数总计不超过公司董事总数的二分之一。 特此公告。 华仁药业股份有限公司董事会 二〇二五年六月二十三日 附件：职工代表董事简历 王梦辰先生，1988 年 3 月出生，中国国籍，中共党员，无境外永久居留权， 硕士研究生学历，公司律师。2020 年至今，历任华仁药业风控经理，供应链部 副总监，董事会办公室副主任，现任综合管理部副部长。 王梦辰先生未持有公司股份，与公司控股股东、实际控制人、其他 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Core Viewpoint - Hainan Pharmaceutical's subsidiary Anhui Hengxing Pharmaceutical has received approval from the National Medical Products Administration for the "Dexamethasone Hydrochloride Injection" registration certificate, which is expected to positively impact the company's development and product line [1] Group 1 - The approved drug is used to treat clinical hypotension caused by vasodilation during anesthesia [1] - The drug is classified as a Category B product under the national medical insurance scheme [1] - The projected domestic hospital sales for Dexamethasone Hydrochloride Injection in 2024 is 119 million yuan [1] Group 2 - The approval will enrich the company's product line and optimize its product structure [1] - The development is seen as a positive influence on the company's growth trajectory [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-038 华仁药业股份有限公司 关于全资子公司盐酸去氧肾上腺素注射液取得药品注册证 书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸去氧肾上腺素注射液"的《药品注册证书》，具体情况公告如下： 一、药品基本情况 1．药品名称 药品通用名称：盐酸去氧肾上腺素注射液 英文名/拉丁名：Phenylephrine Hydrochloride Injection 2．剂型：注射剂 3．申请事项：药品注册（境内生产） 地址：合肥市包河工业区纬五路 15 号 12．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 13．药品批准文号：国药准字 H20254431 14．药品批准文号有效期：至 2030 年 6 月 2 日 二、药品相关情况 盐酸去氧肾上腺素注射液用于治疗麻醉时血管扩张引起的临床低血压，为国 家医保乙类品种。 根据《中华 ...

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. is facing significant financial challenges, including a major loss attributed to credit impairment losses related to receivables from Guoyao Medicinal Materials Co., Ltd. [1][4] Group 1: Shareholder Actions - Huaren Century Group, a major shareholder, plans to reduce its stake in Huaren Pharmaceutical by up to 1% between June 24, 2025, and September 23, 2025, amounting to no more than 11,822,100 shares [1][2] - Huaren Century Group's shareholding has decreased from 53% in 2014 to 7.9% currently, following multiple rounds of share reductions [2][3] - Red Tower Innovation Investment Co., Ltd., the third-largest shareholder, has also been reducing its holdings, having sold 23,619,960 shares for a total of 74.16 million yuan from August 22, 2024, to April 29, 2025 [2] Group 2: Financial Performance - Huaren Pharmaceutical reported a net loss of 1.368 billion yuan for 2024, marking the worst performance since its listing in 2010, effectively erasing all profits accumulated over 13 years [3][4] - The company has cumulatively achieved a net profit of 1.197 billion yuan from 2010 to 2023, indicating that the loss in 2024 surpassed all previous profits [3] Group 3: Credit Impairment and Debt Recovery - The significant loss is primarily due to the full credit impairment of receivables amounting to 1.3478 billion yuan owed by Guoyao Medicinal Materials [4][6] - Huaren Pharmaceutical's subsidiary, Qingdao Huaren Pharmaceutical Co., Ltd., had established a business relationship with Guoyao Medicinal Materials, resulting in 1.41 billion yuan in receivables [4][5] - A repayment agreement was signed in January 2024, allowing Guoyao Medicinal Materials three years to settle the debt, but the execution of this agreement remains uncertain [6] Group 4: Guoyao Medicinal Materials' Issues - Guoyao Medicinal Materials is not controlled by the state-owned China National Pharmaceutical Group, despite its name, and has faced various operational issues [5][6] - The company has multiple enforcement actions against it, totaling 106 million yuan, and has been subject to numerous restrictions and judgments [6]

证券代码：300110 证券简称：华仁药业 公告编号：2025-037 华仁药业股份有限公司 关于参与化学药品省际联盟带量联动采购中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）及全资子公司华仁药业（日照） 有限公司近期积极参与了环磷腺苷葡胺等 66 个化学药品省际联盟带量联动采购 （采购文件编号：SCLM-YP2025-1）的投标工作。根据四川省药械招标采购服务 中心近日公布的中选结果，公司产品血液滤过置换基础液、单硝酸异山梨酯氯化 钠注射液及子公司华仁药业（日照）有限公司产品甘露醇注射液、卡络磺钠氯化 钠注射液中选本次带量联动采购，现将相关情况公告如下： 中选企业 中选产品 注册分类 适应症 规格 中选价格 采购区域 华仁药业股 份有限公司 血液滤过置 换基础液 化学药品 适用于血液滤过治疗时置换体 内的水分和电解质，替代肝脏 部分功能。 4,000ml 14.83 元/袋 四川、重 庆、贵州、 云南、西 藏、青海 单硝酸异山 梨酯氯化钠 注射液 化学药品 适用于治疗心绞痛，与洋地黄 及（或）利尿剂合成治 ...

华仁药业股份有限公司（以下简称"华仁药业"或"公司"）于近日收到持股5% 以上股东华仁世纪集团有限公司（以下简称"华仁世纪集团"）《关于减持华仁药 业股份计划的告知函》，华仁世纪集团计划自减持计划公告之日起十五个交易日 后的三个月内（即2025年6月24日至2025年9月23日）通过集中竞价交易方式减持 不超过公司总股本1%的股份，即不超过11,822,100股。现将具体情况公告如下： 一、减持主体的基本情况 华仁世纪集团持有公司股份 93,365,046 股，占公司总股本的 7.90%。 二、本次减持计划的主要内容 股份因送转股而相应增加的股份）及配股取得的公司股份。 证券代码：300110 证券简称：华仁药业 公告编号：2025-036 华仁药业股份有限公司 关于持股 5%以上股东减持计划预披露的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 的情形。 —股东及董事、高级管理人员减持股份》第五条至第九条规定的情形。华仁世纪 集团在按照本次计划减持股份期间，将严格遵守《证券法》《上市公司收购管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-036 华仁药业股份有限公司 关于持股 5%以上股东减持计划预披露的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"华仁药业"或"公司"）于近日收到持股5% 以上股东华仁世纪集团有限公司（以下简称"华仁世纪集团"）《关于减持华仁药 业股份计划的告知函》，华仁世纪集团计划自减持计划公告之日起十五个交易日 后的三个月内（即2025年6月24日至2025年9月23日）通过集中竞价交易方式减持 不超过公司总股本1%的股份，即不超过11,822,100股。现将具体情况公告如下： 3、减持价格：根据减持时市场价格确定。 4、拟减持股份来源：公司首次公开发行股票前其持有的公司股份（含该等 股份因送转股而相应增加的股份）及配股取得的公司股份。 5、股份性质：无限售流通股。 6、拟减持期间：自本减持计划公告之日起十五个交易日后的三个月内（即 2025年6月24日至2025年9月23日）。 一、减持主体的基本情况 1、减持主体的名称：华仁世纪集团有限公司。 2、减持主体持有股份的 ...